ABSTRACT - 591008 The disclosure relates to the use of a DPP-4 inhibitor such as 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine which is represented by either of the formulae (I) (II) (III) or (IV) and pharmaceutically acceptable salt wherein the variables are as defined in the specification. These compounds are suitable for wound healing preferably in diabetic patients or for reducing destructive wound inflammation such as e.g. for reducing...

A method of preparing a pharmaceutical dosage form having a first and second active drug comprising(a) forming a controlled release core comprising metformin or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient;(b) coating a coating solution on said controlled release core to form an immediate release coating said coating solution comprising:(i) pioglitazone or a pharmaceutically acceptable salt thereof;(ii) water;(iii) an organic solvent;(iv) a bi...

Provided is a sustained-release preparation containing pioglitazone or a salt thereof as an active ingredient and showing superior sustainability. A sustained-release preparation containing pioglitazone or a salt thereof which shows a dissolution ratio of pioglitazone of average 25-58% at the 2-hour time point and average 60-100% at the 4-hour time point in a dissolution test according to the 50 rpm USP Paddle Method and using pH 2.0 KCl/HCl buffer at 37 DEG C as a test solution.

A novel process for preparing thiazolidinediones preferably Pioglitazone as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.